IMGN-151 is under clinical development by ImmunoGen and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I drugs for Peritoneal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMGN-151’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMGN-151 is under development for the treatment of epithelial ovarian cancer, endometrial, primary peritoneal and fallopian tube cancers. It acts by targeting folate receptor 1 (FOLR1). The drug candidate is developed based on antibody-drug conjugate (ADC) platform technology. It is administered through intravenous route.
It was also under development for triple-negative breast cancer, non-small cell lung cancer, breast and cervical cancer.
ImmunoGen is a clinical-stage biotechnology company that focuses on the development of novel antibody-drug conjugates (ADCs) that facilitate targeted therapies for the treatment of cancer. Its pipeline product candidates include mirvetuximab soravtansine for the treatment of platinum-resistant ovarian cancer; IMGN632 for AML, and blastic plasmacytoid dendritic cell neoplasm (BPDCN); IMGC936, the company’s product candidate for a range of solid tumors; and IMGN151, its next-generation anti-FRa candidate in the preclinical development stage. ImmunoGenorporates its proprietary product development ADC technology to enhance the anticancer activity of monoclonal antibodies. The company has direct operations in the US, Ireland, and the UK. ImmunoGen is headquartered in Waltham, Massachusetts, the US.
For a complete picture of IMGN-151’s drug-specific PTSR and LoA scores, buy the report here.